Nonprofit Organizations Join Forces to Evaluate Adjuvants for Pandemic Flu Vaccines

PATH and the Infectious Disease Research Institute (IDRI) are teaming up to evaluate whether the latter’s emulsion adjuvants can boost the immune response to develop pandemic flu vaccines. PATH will provide the vaccine candidates and sponsor research at IDRI aimed at identifying promising vaccine-adjuvant combinations.

“The collaboration is an important step toward enhancing the cost-effectiveness of influenza vaccines and expanding their availability to low-resource countries that would not otherwise be able to access them,” remarks Kathleen Neuzil, M.D., director of PATH’s influenza vaccine project.